Health Food Lab, Kolmar BNH Co., LTD, Seoul, Korea.
Department of Pharmacology, Laila Nutraceuticals R&D Center, Vijayawada, Andhra Pradesh, India.
J Am Nutr Assoc. 2024 Jan;43(1):48-58. doi: 10.1080/27697061.2023.2209880. Epub 2023 May 24.
NXT15906F6 (TamaFlex) is a proprietary herbal composition containing seeds and rhizome extracts. NXT15906F6 supplementation has been shown clinically effective in reducing knee joint pain and improving musculoskeletal functions in healthy and knee osteoarthritis (OA) subjects. The objective of the present study was to assess the possible molecular basis of the anti-OA efficacy of NXT15906F6 in a monosodium iodoacetate (MIA)-induced model of OA in rats.
Healthy male Sprague Dawley rats (age: 8-9 wk body weight, B.W.: 225-308 g ( = 12) were randomly assigned to one of the six groups, (a) vehicle control, (b) MIA control, (c) Celecoxib (10 mg/kg B.W.), (d) TF-30 (30 mg/kg B.W.), (e) TF-60 (60 mg/kg B.W.), and (f) TF-100 (100 mg/kg B.W.). OA was induced by an intra-articular injection of 3 mg MIA into the right hind knee joint. The animals received either Celecoxib or TF through oral gavage over 28 days. The vehicle control animals received intra-articular sterile normal saline.
Post-treatment, NXT15906F6 groups showed significant ( < 0.05) dose-dependent pain relief as evidenced by improved body weight-bearing capacity on the right hind limb. NXT15906F6 treatment also significantly reduced the serum tumor necrosis factor-α (TNF-α, < 0.05) and nitrite ( < 0.05) levels in a dose-dependent manner. mRNA expression analyses revealed the up-regulation of collagen type-II (COL2A1) and down-regulation of matrix metalloproteinases (MMP-3, MMP-9 and MMP-13) in the cartilage tissues of NXT15906F6-supplemented rats. Cyclooxygenase-2 and inducible nitric oxide synthase (iNOS) protein expressions were down-regulated. Decreased immunolocalization of NF-κβ (p65) was observed in the joint tissues of NXT15906F6-supplemented rats. Furthermore, microscopic observations revealed that NXT15906F6 preserved MIA-induced rats' joint architecture and integrity.
NXT15906F6 reduces MIA-induced joint pain, inflammation, and cartilage degradation in rats.
NXT15906F6（TamaFlex）是一种含 种子和 根茎提取物的专利草药组合物。临床研究表明，NXT15906F6 补充剂可有效减轻健康人群和膝骨关节炎（OA）患者的膝关节疼痛，改善骨骼肌肉功能。本研究旨在评估 NXT15906F6 对 MIA 诱导的 OA 大鼠模型的抗 OA 作用的可能分子基础。
健康雄性 Sprague Dawley 大鼠（年龄：8-9 周，体重：225-308 g（=12））随机分为 6 组，（a） vehicle 对照组，（b） MIA 对照组，（c） Celecoxib（10 mg/kg 体重），（d） TF-30（30 mg/kg 体重），（e） TF-60（60 mg/kg 体重）和（f） TF-100（100 mg/kg 体重）。通过关节内注射 3mg MIA 诱导右侧后肢膝关节 OA。动物通过口服灌胃给予 Celecoxib 或 TF 28 天。vehicle 对照组动物接受关节内无菌生理盐水注射。
治疗后，NXT15906F6 各剂量组右后肢负重能力明显改善（ < 0.05），提示疼痛缓解呈剂量依赖性。NXT15906F6 治疗还可显著降低血清肿瘤坏死因子-α（TNF-α， < 0.05）和亚硝酸盐（ < 0.05）水平，呈剂量依赖性。软骨组织中 COL2A1 表达上调，MMP-3、MMP-9 和 MMP-13 表达下调。COX-2 和诱导型一氧化氮合酶（iNOS）蛋白表达下调。在 NXT15906F6 治疗组关节组织中 NF-κβ（p65）的免疫定位减少。此外，显微镜观察显示，NXT15906F6 可维持 MIA 诱导的大鼠关节结构和完整性。
NXT15906F6 可减轻 MIA 诱导的大鼠关节疼痛、炎症和软骨降解。
